AHEALTH 7090 Share Price
RM3.00
52 Weeks Range : 2 - 4.55
4.2/10
(Expert Score)
Product is rated as #12 in category BM Health Care
PROS:
- Positive Cash Company
- Low Gearing Ratio
- High Trading Liquidity
CONS:
- Very Low Price-to-Tangible
klse: Apex Healthcare Bhd
Corporate Information
Board : Main
Shariah : Shariah Compliant
Sector : Ringgit Consumer Healthcare
Address: 1-5, Jalan TTC 1, Cheng Industrial Estate Melaka, Cheng, 75250, Melaka
Contact: +606-3370980
Website: https://www.apexhealthcare.com.my/
Corporate Background
Apex Healthcare Berhad operates as a holding company. The Company, through its subsidiaries, offers development, manufacturing, sales and marketing, distribution, and wholesaling of pharmaceuticals, consumer health care, and diagnostics products. Apex Healthcare serves customers in Malaysia.
Genaral Info: AHEALTH 7090
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 25/02/21 | 161,577 | 18,401 | 14,394 |
| 19/11/20 | 169,116 | 17,488 | 14,223 |
| 26/08/20 | 174,728 | 16,341 | 13,034 |
| 21/05/20 | 193,308 | 17,944 | 14,370 |
| 19/02/20 | 170,634 | 18,484 | 14,004 |
| 21/11/19 | 180,653 | 17,124 | 14,123 |
| 21/08/19 | 159,270 | 16,183 | 13,224 |
| 23/05/19 | 178,229 | 14,543 | 11,399 |
| 28/02/19 | 163,061 | 16,739 | 16,804 |
| 15/11/18 | 165,253 | 18,637 | 14,897 |
| 16/08/18 | 155,946 | 17,368 | 13,699 |
| 24/05/18 | 168,400 | 16,526 | 13,181 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 698,729 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | 56,011 |
| Last 4 Quarter EPS (sen) | 11.84 |
| Last 4 Quarter PER | 25.46 |
| Last 4 Quarter Dividend (sen) | 4.50 |
| Last 4 Quarter Dividend Yield (%) | 1.50 |
| Net Tangible Assets (RM) | 0.99 |
| Goodwill (RM) | 1,590 |
| Cash (RM’000) | 162,100 |
| Debt (RM’000) | 27,580 |
| Total Debt (RM’000) | 157,840 |
| Net Assets (RM’000) | 453,030 |
| Current Ratio | 2.88 |
| Quick Ratio | 2.20 |
| Cash Ratio | 1.23 |
Technical
Technical Analysis
| MACD (26 vs 12) | -0.043 |
|---|---|
| Exponential Moving Average 5 | 2.975 |
| Exponential Moving Average 20 | 2.995 |
| Exponential Moving Average 90 | 3.213 |
| Relative Strength Index 14 | 0.41 |
| Stochastic %D 3 | 0.36 |
| Stochastic %K 14 | 0.50 |
5 reviews for AHEALTH 7090
Show all
Most Helpful
Highest Rating
Lowest Rating
BURSA MALAYSIA –
Profit before tax for the current quarter at RM 17.5 million is 7.0% better than the RM 16.3 million achieved in the immediate preceding quarter. This is due to lower operating expenses as well as a greater percentage of higher margin products in the sales mix.
REMUNERATION STUDY –
In Financial Year End 2019, the directors’ remuneration was 3.32 million. It was fair compared to average in listed companies, considering the employees’ remuneration of 69.5 million and auditor’s remuneration of 289 thousands
BURSA MALAYSIA –
Profit before tax for the current quarter is RM 17.9 million compared to RM 18.5 million reported for the last quarter of 2019. There is no material change in the profit before taxation for the quarter reported on as compared with preceding quarter.
BURSA MALAYSIA –
Profit before taxation for the current quarter is RM 18.5 million, 7.9% better than the RM 17.1 million reported for 3Q2019. There is mainly attributed to a greater percentage of manufacturing segment sales which carry better margins in the Group’s consolidated revenue.
Investing Malaysia –
Average investing volume for Apex Healthcare Bhd in the past three months in stock market was 75k lots
Investing Malaysia –
AHEALTH gets a score of 12.21 in our equity and assets quality test based on current share price of RM2.4
Investing Malaysia –
Apex Healthcare Bhd gets a score of 21.94 in our stability test after the balance sheet, money statement study
Investing Malaysia –
Stock code of 7090 in Bursa Malaysia declared adjusted 1.58% dividend yield in past few years
Investing Malaysia –
AHEALTH is estimated to have a profit consensus of 71.15 millions, with an adjusted market capitalization of 1086.16 millions
REMUNERATION STUDY –
In Financial Year End 2018, the directors’ remuneration was 3.8 million. It was fair compared to average in listed companies, considering the employees’ remuneration of 65.8 million and auditor’s remuneration of 281 thousands